Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously reported Heavily pre-treated patient had failed 8 prior regimens including antibody-drug conjugate (ADC)... Read More